MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.56
+0.12
+0.96%
After Hours: 12.56 0 0.00% 17:52 05/07 EDT
OPEN
12.47
PREV CLOSE
12.44
HIGH
12.76
LOW
12.40
VOLUME
698.05K
TURNOVER
--
52 WEEK HIGH
29.65
52 WEEK LOW
12.16
MARKET CAP
628.52M
P/E (TTM)
380.61
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6)
Benzinga · 1d ago
Cara Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference
STAMFORD, Conn., May 06, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa o...
GlobeNewswire · 2d ago
Stocks That Hit 52-Week Lows On Thursday
    During the morning session on Thursday, 67 stocks hit new 52-week lows.
Benzinga · 2d ago
Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
STAMFORD, Conn., May 03, 2021 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa o...
GlobeNewswire · 5d ago
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Zacks · 5d ago
Cannabis Stock Gainers And Losers From April 30, 2021
GAINERS: Rhinomed (OTC: RHNMF) shares closed up 106% at $0.10
Benzinga · 04/30 23:27
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs.
Benzinga · 04/30 09:22
Cannabis Stock Gainers And Losers From April 29, 2021
GAINERS: RIV Capital (OTC: CNPOF) shares closed up 13.18% at $1.98
Benzinga · 04/29 22:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CARA. Analyze the recent business situations of Cara through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CARA stock price target is 29.13 with a high estimate of 37.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 227
Institutional Holdings: 33.52M
% Owned: 66.99%
Shares Outstanding: 50.04M
TypeInstitutionsShares
Increased
45
1.81M
New
22
189.80K
Decreased
48
2.46M
Sold Out
25
252.01K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
President/Chief Executive Officer/Director
Derek Chalmers
Chief Financial Officer
Thomas Reilly
Senior Vice President/Chief Scientific Officer
Frederique Menzaghi
Chief Compliance Officer/General Counsel/Secretary
Scott Terrillion
Vice President/Controller
Richard Makara
Other
Joana Goncalves
Lead Director/Independent Director
Martin Vogelbaum
Director
Susan Shiff
Independent Director
Harrison Bains
Independent Director
Jeffrey Ives
Independent Director
Christopher Posner
No Data
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.